• SENSEX
    NIFTY 50
Economy

10 things you need to know before the opening bell on December 15

Updated : December 15, 2020 07:54 AM IST

The Indian market is likely to open on a tepid note Tuesday following a mixed trend in global peers. At 7:00 am, the SGX Nifty was trading 27.00 points or 0.20 percent lower at 13,564.50, indicating a negative start for the Sensex and Nifty50.

1. Asia: Stocks in Asia-Pacific were lower in Tuesday trade as concerns over a coronavirus surge in multiple countries dulled optimism over the vaccine rollout in the U.S. Mainland Chinese markets were lower in early trade: The Shanghai composite declined 0.31 percent while the Shenzhen component dipped 0.212 percent. Hong Kong’s Hang Seng index was fractionally lower. In Japan, the Nikkei 225 dipped 0.16 percent while the Topix index traded 0.23 percent lower. South Korea’s Kospi shed 0.24 percent, reported CNBC International. (Image: Reuters)
1. Asia: Stocks in Asia-Pacific were lower in Tuesday trade as concerns over a coronavirus surge in multiple countries dulled optimism over the vaccine rollout in the U.S. Mainland Chinese markets were lower in early trade: The Shanghai composite declined 0.31 percent while the Shenzhen component dipped 0.212 percent. Hong Kong’s Hang Seng index was fractionally lower. In Japan, the Nikkei 225 dipped 0.16 percent while the Topix index traded 0.23 percent lower. South Korea’s Kospi shed 0.24 percent, reported CNBC International. (Image: Reuters)
2. US: The Dow Jones Industrial Average and S&P 500 fell on Monday as fears of additional Covid-19 restrictions offset the optimism around a vaccine rollout. The 30-stock Dow closed lower by 184.82 points, or 0.6 percent, at 29,861.55. At its session high, the Dow was up more than 200 points and hit an all-time high. The S&P 500 declined by 0.4 percent to 3,647.49, posting its first four-day losing streak since September 21. The Nasdaq Composite outperformed, rising 0.5 percent to 12,440.04. New York City Mayor Bill De Blasio warned earlier in the day that the city could experience a “full shutdown” soon. His comments put pressure on the Dow and S&P 500 reported CNBC International. (Image: AP)
2. US: The Dow Jones Industrial Average and S&P 500 fell on Monday as fears of additional Covid-19 restrictions offset the optimism around a vaccine rollout. The 30-stock Dow closed lower by 184.82 points, or 0.6 percent, at 29,861.55. At its session high, the Dow was up more than 200 points and hit an all-time high. The S&P 500 declined by 0.4 percent to 3,647.49, posting its first four-day losing streak since September 21. The Nasdaq Composite outperformed, rising 0.5 percent to 12,440.04. New York City Mayor Bill De Blasio warned earlier in the day that the city could experience a “full shutdown” soon. His comments put pressure on the Dow and S&P 500 reported CNBC International. (Image: AP)
3. Markets At Close On Monday: The Indian stock market ended higher on Monday on the back of gains in banks, metals, pharma and FMCG stocks. The Sensex ended 154 points higher to 46,253 while the Nifty50 index closed at 13,558, up 44 points higher. However, broader markets continued to outperform benchmarks with the Nifty Midcap and Nifty Smallcap indices up more than half a percent each. Barring auto and realty indexes, all sectoral indices ended higher. Nifty Media was the best-performing index of the day, ending 2 percent higher followed by Nifty PSU Bank and Nifty Metal. (Image: Reuters)
3. Markets At Close On Monday: The Indian stock market ended higher on Monday on the back of gains in banks, metals, pharma and FMCG stocks. The Sensex ended 154 points higher to 46,253 while the Nifty50 index closed at 13,558, up 44 points higher. However, broader markets continued to outperform benchmarks with the Nifty Midcap and Nifty Smallcap indices up more than half a percent each. Barring auto and realty indexes, all sectoral indices ended higher. Nifty Media was the best-performing index of the day, ending 2 percent higher followed by Nifty PSU Bank and Nifty Metal. (Image: Reuters)
4. Crude Oil: Oil prices gained on Monday amid hopes that a rollout of coronavirus vaccines will lift global fuel demand. Brent crude futures for February rose 32 cents, or 0.6 percent, to $50.29 a barrel, while U.S. West Texas Intermediate crude futures for January were up 42 cents, or 0.9 percent, at $46.99 a barrel, its highest level in nine months. Brent and WTI have rallied for six consecutive weeks, their longest stretch of weekly gains since June, reported CNBC International. (Image: Reuters)
4. Crude Oil: Oil prices gained on Monday amid hopes that a rollout of coronavirus vaccines will lift global fuel demand. Brent crude futures for February rose 32 cents, or 0.6 percent, to $50.29 a barrel, while U.S. West Texas Intermediate crude futures for January were up 42 cents, or 0.9 percent, at $46.99 a barrel, its highest level in nine months. Brent and WTI have rallied for six consecutive weeks, their longest stretch of weekly gains since June, reported CNBC International. (Image: Reuters)
5. Rupee Close: The Indian currency advanced by 9 paise to settle at 73.55 (provisional) against the US dollar on Monday, buoyed by sustained foreign fund inflows and heavy buying in domestic equities. Traders said upbeat industrial production data and weakening of the American currency in the overseas market also supported the rupee. At the interbank forex market, the domestic unit opened at 73.62 against the US dollar, then gained ground and touched an intra-day high of 73.48 against the greenback. The local unit finally closed at 73.55 against the American currency, registering a rise of 9 paise over its previous close, reported PTI. (Image: Reuters)
5. Rupee Close: The Indian currency advanced by 9 paise to settle at 73.55 (provisional) against the US dollar on Monday, buoyed by sustained foreign fund inflows and heavy buying in domestic equities. Traders said upbeat industrial production data and weakening of the American currency in the overseas market also supported the rupee. At the interbank forex market, the domestic unit opened at 73.62 against the US dollar, then gained ground and touched an intra-day high of 73.48 against the greenback. The local unit finally closed at 73.55 against the American currency, registering a rise of 9 paise over its previous close, reported PTI. (Image: Reuters)
8. Retail Inflation In November Declines: Retail inflation declined to 6.93 per cent in November on softer food prices, though it remained above the comfort level of the Reserve Bank. Retail inflation based on the Consumer Price Index (CPI) stood at 7.61 per cent in October. According to the CPI data released by the government on Monday, inflation in the food basket was 9.43 per cent in November, down from 11 per cent in the previous month. The RBI, which mainly factors in retail inflation while arriving at key policy rates, has been mandated by the government to keep inflation at 4 per cent (+, - 2 per cent). The central bank had maintained status quo in the policy rate earlier this month due to high inflation. (Image: Reuters)
8. Retail Inflation In November Declines: Retail inflation declined to 6.93 per cent in November on softer food prices, though it remained above the comfort level of the Reserve Bank. Retail inflation based on the Consumer Price Index (CPI) stood at 7.61 per cent in October. According to the CPI data released by the government on Monday, inflation in the food basket was 9.43 per cent in November, down from 11 per cent in the previous month. The RBI, which mainly factors in retail inflation while arriving at key policy rates, has been mandated by the government to keep inflation at 4 per cent (+, - 2 per cent). The central bank had maintained status quo in the policy rate earlier this month due to high inflation. (Image: Reuters)
9. DHFL Receives Highest Bidder: US-based Oaktree Capital Management has outbid rivals Piramal and Adani Group to emerge as the highest bidder for Dewan Housing Finance Limited (DHFL) in the fourth round of bidding, multiple people involved in the deal told CNBC-TV18. Of the three bids received for the entire portfolio of DHFL, Adani Group has surprisingly offered the least as per the latest bids received this morning. The deadline to submit bids ended this morning, and three suitors submitted new bids for the entire portfolio, CNBC-TV18 reported earlier today. Oaktree Capital raised its offer to a total of Rs 36,646 crores to acquire the entire DHFL book, three people independently confirmed to CNBC-TV18. This includes an upfront cash payment of Rs 11,646 crores to the financial creditors. However, the total offer also includes Rs 3,000 crores interest earned from cash on DHFL’s books, and another Rs 1,000 crores of notional gain from the sale of DHFL’s stake in Pramerica Life Insurance, said people in the know. Excluding the Rs 3,000 crores interest component and gain from insurance business sale, Oaktree Capital’s offer would come to about Rs 32,646 crores. (Image: Reuters)
9. DHFL Receives Highest Bidder: US-based Oaktree Capital Management has outbid rivals Piramal and Adani Group to emerge as the highest bidder for Dewan Housing Finance Limited (DHFL) in the fourth round of bidding, multiple people involved in the deal told CNBC-TV18. Of the three bids received for the entire portfolio of DHFL, Adani Group has surprisingly offered the least as per the latest bids received this morning. The deadline to submit bids ended this morning, and three suitors submitted new bids for the entire portfolio, CNBC-TV18 reported earlier today. Oaktree Capital raised its offer to a total of Rs 36,646 crores to acquire the entire DHFL book, three people independently confirmed to CNBC-TV18. This includes an upfront cash payment of Rs 11,646 crores to the financial creditors. However, the total offer also includes Rs 3,000 crores interest earned from cash on DHFL’s books, and another Rs 1,000 crores of notional gain from the sale of DHFL’s stake in Pramerica Life Insurance, said people in the know. Excluding the Rs 3,000 crores interest component and gain from insurance business sale, Oaktree Capital’s offer would come to about Rs 32,646 crores. (Image: Reuters)
10. Sputnik V Vaccine Efficacy Is 91.4%: The efficacy of Sputnik V vaccine is 91.4 percent, based on the final control point analysis of data obtained 21 days after administering the first dose, according to a statement issued by Russian Direct Investment Fund (RDIF) and Gamelya Institute on Monday. The vaccine efficacy against severe cases of coronavirus was 100 percent. Among the confirmed cases of coronavirus infection, 20 severe cases were recorded in the placebo group, while no severe cases were recorded in the vaccine group, the statement said. The analysis of the efficacy at the final control point was carried out on the basis of 78 confirmed cases identified in the placebo group (62 cases) and in the vaccine group (16 cases). The ratio of the placebo group to the vaccinated group is 1 to 3. As per official figure, by now more than 26,000 volunteers have been vaccinated as part of double-blind, randomised, placebo-controlled Phase III post-registration clinical trials of Sputnik V in Russia. (Image: AP)
10. Sputnik V Vaccine Efficacy Is 91.4%: The efficacy of Sputnik V vaccine is 91.4 percent, based on the final control point analysis of data obtained 21 days after administering the first dose, according to a statement issued by Russian Direct Investment Fund (RDIF) and Gamelya Institute on Monday. The vaccine efficacy against severe cases of coronavirus was 100 percent. Among the confirmed cases of coronavirus infection, 20 severe cases were recorded in the placebo group, while no severe cases were recorded in the vaccine group, the statement said. The analysis of the efficacy at the final control point was carried out on the basis of 78 confirmed cases identified in the placebo group (62 cases) and in the vaccine group (16 cases). The ratio of the placebo group to the vaccinated group is 1 to 3. As per official figure, by now more than 26,000 volunteers have been vaccinated as part of double-blind, randomised, placebo-controlled Phase III post-registration clinical trials of Sputnik V in Russia. (Image: AP)
Published : December 15, 2020 07:54 AM IST
Live TV

recommended for you

Ask Our Experts CNBC TV18

Advertisement